AUTL Stock Summary and Trading Ideas (Autolus Therapeutics PLC - American Depositary Shares | NASDAQ:AUTL)

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.

As of January 29, 2025, AUTL stock price declined to $2.14 with 980,765 million shares trading.

AUTL has a beta of 1.66, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.08 to the broad based SPY ETF.

AUTL has a market cap of $569.08 million. This is considered a Small Cap stock.

Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $0 in Revenue and -$.31 earnings per share. This fell short of revenue expectation by $-130,000 and missed earnings estimates by -$.10.

In the last 3 years, AUTL traded as high as $7.45 and as low as $1.60.

The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, SBIO, KOMP, CANC, FFSM.

AUTL has underperformed the market in the last year with a price return of -64.0% while the SPY ETF gained +24.9%. AUTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.0% and -3.2%, respectively, while the SPY returned +4.0% and +3.4%, respectively.

AUTL support price is $2.11 and resistance is $2.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.